Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IPA's Jain On The Journey So Far And Fires To Douse

Executive Summary

Sudarshan Jain, the new secretary general of the Indian Pharmaceutical Alliance and ex-Abbott managing director, wears many hats, including that of a senior advisor with a private equity advisory firm. He recounts having “survived in different cultures” in his career and outlines the priorities in his new role, amid continuing questions around generic quality.

You may also be interested in...



Events And Losses That Shook India Pharma In The Decade

The past decade witnessed a bout of pharma 'shock and awe' events in India, some of which still reverberate across the industry. The period also marked the death of doyens of the Indian pharmaceutical sector, including the founders of Dr Reddy’s and Lupin.

Top India Drugmakers’ Body Names Industry Veteran Sudarshan Jain New Secretary General

The Indian Pharmaceutical Alliance, which has been at the forefront in representing the interests of the country’s large domestic generic drugmakers, has appointed industry veteran Sudarshan Jain as its new secretary general, replacing founder Dilip Shah who died in February.

Obituary: Indian Generics Industry Torchbearer Dilip Shah

Indian industry veteran and secretary general of the Indian Pharmaceutical Alliance, Dilip Shah, has died aged 77. Shah, a former commercial director of Pfizer in India, played a pivotal role in ensuring that the Indian generic industry's voice was heard.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC125216

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel